These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37311724)

  • 1. Liver fibrosis markers and all cause mortality in people with type 2 diabetes: A population based study (The Ayrshire Diabetes Outcomes Cohort (ADOC) Study).
    Collier A; Curran C; Cameron L; Wild SH; Byrne CD
    Diabetes Obes Metab; 2023 Sep; 25(9):2659-2668. PubMed ID: 37311724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance of non-invasive liver fibrosis scores for mortality and complications development in individuals with type 2 diabetes.
    Leite NC; Cardoso CRL; Salles GF
    J Diabetes Complications; 2021 May; 35(5):107879. PubMed ID: 33573891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Noninvasive Fibrosis Markers and Postoperative Mortality After Hepatectomy for Hepatocellular Carcinoma.
    Maegawa FB; Shehorn L; Aziz H; Kettelle J; Jie T; Riall TS
    JAMA Netw Open; 2019 Jan; 2(1):e187142. PubMed ID: 30657533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications.
    Ciardullo S; Muraca E; Perra S; Bianconi E; Zerbini F; Oltolini A; Cannistraci R; Parmeggiani P; Manzoni G; Gastaldelli A; Lattuada G; Perseghin G
    BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32049637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical profile of non-alcoholic fatty liver disease in nonobese patients.
    Lum JHM; Cheah MCC; Leow WQ; Wan WK; Lim TKH; Chow WC; Chang JPE; Goh GBB
    J Gastroenterol Hepatol; 2021 Jan; 36(1):257-261. PubMed ID: 32557741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States.
    Kim D; Kim WR; Kim HJ; Therneau TM
    Hepatology; 2013 Apr; 57(4):1357-65. PubMed ID: 23175136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-alcoholic fatty liver disease (NAFLD) fibrosis score predicts 6.6-year overall mortality of Chinese patients with NAFLD.
    Xun YH; Guo JC; Lou GQ; Jiang YM; Zhuang ZJ; Zhu MF; Luo Y; Ma XJ; Liu J; Bian DX; Shi JP
    Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):643-9. PubMed ID: 24837195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Utility of Noninvasive Scores in Assessing the Prevalence of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Type 2 Diabetic Patients.
    Singh A; Le P; Peerzada MM; Lopez R; Alkhouri N
    J Clin Gastroenterol; 2018 Mar; 52(3):268-272. PubMed ID: 28787358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrosis Risk in Nonalcoholic Fatty Liver Disease Is Related to Chronic Kidney Disease in Older Type 2 Diabetes Patients.
    Sun Y; Hong L; Huang Z; Wang L; Xiong Y; Zong S; Zhang R; Liu J; Zang S
    J Clin Endocrinol Metab; 2022 Aug; 107(9):e3661-e3669. PubMed ID: 35766414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Six Noninvasive Methods for the Detection of Fibrosis in Chinese Patients with Obesity and Nonalcoholic Fatty Liver Disease.
    Chen G; Yang JC; Zhang GX; Cheng Z; Du X
    Obes Surg; 2022 Nov; 32(11):3619-3626. PubMed ID: 36070119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity and Weight Gain Are Associated With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Kim Y; Chang Y; Cho YK; Ahn J; Shin H; Ryu S
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):543-550.e2. PubMed ID: 30012432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Association between Non-Invasive Hepatic Fibrosis Markers and Cardiometabolic Risk Factors in the Framingham Heart Study.
    Long MT; Pedley A; Massaro JM; Hoffmann U; Fox CS
    PLoS One; 2016; 11(6):e0157517. PubMed ID: 27341207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modified AST to platelet ratio index improves APRI and better predicts advanced fibrosis and liver cirrhosis in patients with non-alcoholic fatty liver disease.
    Huang C; Seah JJ; Tan CK; Kam JW; Tan J; Teo EK; Kwek A; Wong YJ; Tan M; Ang TL; Kumar R
    Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101528. PubMed ID: 33268036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictability of noninvasive liver fibrosis score for cardiac events in patients with nonalcoholic fatty liver disease.
    Shibata N; Ito T; Toyoda H; Tanaka A; Morita Y; Kanzaki Y; Watanabe N; Yoshioka N; Yasuda S; Morishima I
    Nutr Metab Cardiovasc Dis; 2024 Sep; 34(9):2115-2123. PubMed ID: 38664121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High NAFLD fibrosis score in non-alcoholic fatty liver disease as a predictor of carotid plaque development: a retrospective cohort study based on regular health check-up data in China.
    Yu X; Chen C; Guo Y; Tong Y; Zhao Y; Wu L; Sun X; Wu X; Song Z
    Ann Med; 2021 Dec; 53(1):1621-1631. PubMed ID: 34498502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced liver fibrosis and the metabolic syndrome in a primary care setting.
    Schreiner AD; Zhang J; Durkalski-Mauldin V; Livingston S; Marsden J; Bian J; Mauldin PD; Moran WP; Rockey DC
    Diabetes Metab Res Rev; 2021 Nov; 37(8):e3452. PubMed ID: 33759300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.
    Siddiqui MS; Yamada G; Vuppalanchi R; Van Natta M; Loomba R; Guy C; Brandman D; Tonascia J; Chalasani N; Neuschwander-Tetri B; Sanyal AJ;
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1877-1885.e5. PubMed ID: 30616027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: the Edinburgh type 2 diabetes study.
    Morling JR; Fallowfield JA; Guha IN; Nee LD; Glancy S; Williamson RM; Robertson CM; Strachan MW; Price JF;
    J Hepatol; 2014 Feb; 60(2):384-91. PubMed ID: 24512822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.